Bristol-Myers Squibb (BMY) Stock Analysis

Company Profile

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Bristol-Myers Squibb (BMY) posts ROE of 44.01%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

Bristol-Myers Squibb (BMY) keeps 18.47% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

Bristol-Myers Squibb (BMY) turns 33.79% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

Profitability Metrics

Growth

Bristol-Myers Squibb (BMY) grew revenue -0.22%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

No usable EPS growth is available for Bristol-Myers Squibb (BMY) this period, so the earnings-momentum read is skipped.

Growth Metrics

Financial Strength

Bristol-Myers Squibb (BMY) has current ratio of 1.59, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.

Bristol-Myers Squibb (BMY) has debt-to-equity ratio of 1.91, above the industry benchmark range. Debt sits unusually high against shareholders’ equity, leaving the balance sheet more exposed to rate, refinancing, or earnings shocks.

Financial Strength Metrics

Dividends

Bristol-Myers Squibb (BMY) has dividend yield of 3.99%, above the entire industry range. That headline income is large, but yields this far above peers often come from a falling share price or an at-risk payout, so dividend safety matters more than the percentage itself.

Bristol-Myers Squibb (BMY) has payout ratio of 55.88%, above the peer distribution for its industry. The dividend consumes more reported earnings than peers normally do, leaving unusually thin earnings cover.

Dividend Metrics

Valuation

Bristol-Myers Squibb (BMY) trades at P/E ratio of 13.78, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

Bristol-Myers Squibb (BMY) trades at 2.54 on P/S ratio, in the lower sales-valuation quartile for its industry. That points to a cheaper revenue stream than most peers, with margin quality still doing the heavy lifting.

Bristol-Myers Squibb (BMY) trades at 5.43 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

Valuation Metrics